JP2017052786A5 - - Google Patents

Download PDF

Info

Publication number
JP2017052786A5
JP2017052786A5 JP2016221202A JP2016221202A JP2017052786A5 JP 2017052786 A5 JP2017052786 A5 JP 2017052786A5 JP 2016221202 A JP2016221202 A JP 2016221202A JP 2016221202 A JP2016221202 A JP 2016221202A JP 2017052786 A5 JP2017052786 A5 JP 2017052786A5
Authority
JP
Japan
Prior art keywords
alkyl
combination according
combination
cycloalkyl
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016221202A
Other languages
English (en)
Japanese (ja)
Other versions
JP6352368B2 (ja
JP2017052786A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017052786A publication Critical patent/JP2017052786A/ja
Publication of JP2017052786A5 publication Critical patent/JP2017052786A5/ja
Application granted granted Critical
Publication of JP6352368B2 publication Critical patent/JP6352368B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016221202A 2013-03-14 2016-11-14 トリプトファン代謝によって媒介される免疫抑制の阻害剤 Expired - Fee Related JP6352368B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784089P 2013-03-14 2013-03-14
US61/784,089 2013-03-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016501035A Division JP6093903B2 (ja) 2013-03-14 2014-03-10 トリプトファン代謝によって媒介される免疫抑制の阻害剤

Publications (3)

Publication Number Publication Date
JP2017052786A JP2017052786A (ja) 2017-03-16
JP2017052786A5 true JP2017052786A5 (https=) 2017-09-07
JP6352368B2 JP6352368B2 (ja) 2018-07-04

Family

ID=50686105

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016501035A Expired - Fee Related JP6093903B2 (ja) 2013-03-14 2014-03-10 トリプトファン代謝によって媒介される免疫抑制の阻害剤
JP2016221202A Expired - Fee Related JP6352368B2 (ja) 2013-03-14 2016-11-14 トリプトファン代謝によって媒介される免疫抑制の阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016501035A Expired - Fee Related JP6093903B2 (ja) 2013-03-14 2014-03-10 トリプトファン代謝によって媒介される免疫抑制の阻害剤

Country Status (21)

Country Link
US (2) US9617272B2 (https=)
EP (2) EP2976332B1 (https=)
JP (2) JP6093903B2 (https=)
KR (1) KR20150126623A (https=)
CN (1) CN105189466A (https=)
AU (2) AU2014241079C1 (https=)
BR (1) BR112015022588A2 (https=)
CA (1) CA2902174A1 (https=)
CL (2) CL2015002649A1 (https=)
CR (1) CR20150485A (https=)
IL (1) IL241027A0 (https=)
MA (1) MA38493B1 (https=)
MX (1) MX361375B (https=)
PE (1) PE20151593A1 (https=)
PH (1) PH12015501866A1 (https=)
RU (1) RU2667509C2 (https=)
SA (1) SA515361127B1 (https=)
SG (2) SG11201507255QA (https=)
UA (1) UA118103C2 (https=)
WO (1) WO2014159248A1 (https=)
ZA (1) ZA201607948B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (https=) 2011-04-15 2018-03-17
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 P2x7調節劑
WO2014152537A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
PE20151727A1 (es) 2013-03-14 2015-12-17 Boehringer Ingelheim Int Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 P2x7調控劑
ES2654288T3 (es) 2013-03-14 2018-02-13 Janssen Pharmaceutica, N.V. Moduladores de P2X7
CN103570727B (zh) 2013-11-12 2015-08-19 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用
SG10201804868PA (en) * 2014-09-05 2018-07-30 Merck Patent Gmbh Compounds for the inhibition of indoleamine-2,3-dioxygenase
WO2016039983A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulating n-acyl-triazolopyrazines
KR102510588B1 (ko) 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 스피로사이클릭 억제제
CA2960968A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
RU2719446C2 (ru) 2014-11-03 2020-04-17 Айомет Фарма Лтд Фармацевтическое соединение
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
CN105884828A (zh) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
JP6806342B2 (ja) * 2015-04-10 2021-01-06 ベイジーン リミテッド インドールアミンとしての新規5又は8−置換イミダゾ[1,5−a]ピリジン類、及び/又はトリプトファン2,3−ジオキシゲナーゼ
JP2018511647A (ja) 2015-04-12 2018-04-26 ハンジョウ イノゲート ファーマ カンパニー リミテッドHangzhou Innogate Pharma Co.,Ltd. Ido阻害剤とtdo阻害剤としての複素環化合物
BR112017024331A2 (pt) * 2015-05-15 2018-07-24 Gilead Sciences, Inc. composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN105037371A (zh) * 2015-06-30 2015-11-11 西华大学 一种氘代的吲哚胺-2,3-双加氧酶抑制剂
EP3954369B1 (en) 2015-07-24 2025-08-20 Lumos Pharma, Inc. Salts and prodrugs of 1-methyl-d-tryptophan
TW201730190A (zh) 2015-12-24 2017-09-01 Genentech Inc Tdo2抑制劑
CN107056785B (zh) * 2016-01-02 2021-06-22 杭州英创医药科技有限公司 作为ido和tdo抑制剂的杂环化合物
AU2017215424A1 (en) * 2016-02-02 2018-08-09 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
CN112898309A (zh) * 2016-02-19 2021-06-04 正大天晴药业集团股份有限公司 作为免疫调节剂的三并环化合物
CN108884104B (zh) * 2016-02-19 2021-01-15 正大天晴药业集团股份有限公司 作为免疫调节剂的三并环化合物
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
BR112018071602B1 (pt) * 2016-04-29 2024-02-27 Iomet Pharma Ltd. Compostos de imidazopiridina substituídos, sua composição e seus usos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3- dioxigenase
WO2017198159A1 (zh) * 2016-05-16 2017-11-23 鲁南制药集团股份有限公司 含桥环的咪唑衍生物
CN107383012B (zh) * 2016-05-16 2021-09-28 鲁南制药集团股份有限公司 含二环的咪唑醇衍生物
CN107663159A (zh) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
WO2018053529A1 (en) 2016-09-19 2018-03-22 University Of South Florida Method of targeting oncolytic viruses to tumors
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ido及tdo調節之化合物及方法以及其適應症
EP3515914A4 (en) 2016-09-24 2020-04-15 BeiGene, Ltd. INNOVATIVE 5- OR 8-SUBSTITUTED IMIDAZO [1,5-A] PYRIDINE AS SELECTIVE INHIBITORS OF INDOLEAMINE AND / OR TRYPTOPHANE-2,3-DIOXYGENASES
BR112019006652A2 (pt) 2016-10-13 2019-07-02 Juno Therapeutics Inc métodos e composições para imunoterapia envolvendo moduladores da via metabólica do triptofano
TW201815793A (zh) * 2016-10-21 2018-05-01 江蘇恆瑞醫藥股份有限公司 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法
CN108203438B (zh) * 2016-12-20 2021-09-28 深圳微芯生物科技股份有限公司 具有吲哚胺2,3-双加氧酶抑制活性的稠合咪唑化合物
SMT202100573T1 (it) 2016-12-22 2021-11-12 Calithera Biosciences Inc Composizioni e metodi per l'inibizione dell'attivita' dell'arginasi
JP2020506895A (ja) 2017-01-17 2020-03-05 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System インドールアミン2,3−ジオキシゲナーゼおよび/またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物
EP3645533B1 (en) 2017-06-28 2025-03-26 Genentech, Inc. Tdo2 and ido1 inhibitors
US11827639B2 (en) 2017-06-28 2023-11-28 Genentech, Inc. TDO2 and IDO1 inhibitors
CN109384791B (zh) * 2017-08-09 2020-09-11 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
JP6934562B2 (ja) * 2017-08-22 2021-09-15 ギリアード サイエンシーズ, インコーポレイテッド 治療用複素環式化合物
MA50254A (fr) * 2017-09-15 2020-07-22 Taiho Pharmaceutical Co Ltd Agent prophylactique et/ou thérapeutique pour des maladies impliquant l'expression de l'ido
WO2019078246A1 (ja) * 2017-10-19 2019-04-25 一般社団法人ファルマバレープロジェクト支援機構 Ido/tdo阻害剤
CN111386114A (zh) 2017-11-25 2020-07-07 百济神州有限公司 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑
EP3697423A4 (en) 2018-01-05 2021-08-11 Dicerna Pharmaceuticals, Inc. REDUCED EXPRESSION OF BETA-CATENIN AND IDO TO POTENTIALIZE IMMUNOTHERAPY
AU2019239952A1 (en) 2018-03-20 2020-10-08 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
WO2020018670A1 (en) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
KR102833434B1 (ko) * 2018-09-27 2025-07-15 쉔젠 칩스크린 바이오사이언스 씨오., 엘티디. 인돌아민-2,3-디옥시게나아제 억제 활성을 갖는 퀴놀린 유도체
EP3856178B1 (en) 2018-09-28 2026-03-11 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
WO2020065614A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
MX2022003819A (es) 2019-09-30 2022-05-11 Janssen Pharmaceutica Nv Ligandos de pet de mgl radiomarcados.
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
WO2022184930A2 (en) 2021-03-05 2022-09-09 Universität Basel Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH516573A (de) * 1967-08-15 1971-12-15 Sandoz Ag Verfahren zur Herstellung von 5-Hydroxy-5-phenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindolen
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
EP1501918A4 (en) 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
WO2004094409A1 (en) 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
DE102007020493A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Amid-Derivate
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ido阻害剤
JP2011518841A (ja) * 2008-04-24 2011-06-30 ニューリンク ジェネティクス, インコーポレイテッド Ido阻害剤
US8541595B2 (en) * 2008-11-13 2013-09-24 Merch Sharp & Dohme Corp. Imidazoisoindole neuropeptide S receptor antagonists
US8722720B2 (en) * 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
JP2012037986A (ja) 2010-08-04 2012-02-23 Canon Inc 画像形成装置及びその制御方法と画像形成システム
NO2694640T3 (https=) * 2011-04-15 2018-03-17

Similar Documents

Publication Publication Date Title
JP2017052786A5 (https=)
JP2017149769A5 (https=)
US11618749B2 (en) Compounds and compositions for treating conditions associated with STING activity
TWI796526B (zh) Pd-1/pd-l1抑制劑
KR102736865B1 (ko) 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
JP7756643B2 (ja) Sting活性に関連する状態を治療するための化合物および組成物
JP6182278B2 (ja) Toll様レセプター調節4,6−ジアミノ−ピリド[3,2−d]ピリミジン化合物
TWI671297B (zh) 治療癌症及非腫瘤病症之方法
US8980909B2 (en) HDAC inhibiting derivatives of camptothecin
JP2024102170A (ja) Sting活性に関連する状態を治療するための化合物および組成物
CN115279770A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
TWI786242B (zh) 活化sting轉接蛋白之具有膦酸酯鍵之3’3’環二核苷酸
JP2014503567A5 (https=)
CN112204006A (zh) 整合应激通路的调节剂
WO2021067801A1 (en) Compounds and compositions for treating conditions associated with sting activity
CN113382772A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
HRP20110566T1 (hr) Azaindoli kao inhibitori jak i drugih kinaza
CN107087409A (zh) 苯并杂环化合物及其应用
JP2017510663A (ja) Mertk特異的ピリミジン化合物
JP2011526917A5 (https=)
JP2022535743A (ja) Sting活性に関連する状態を治療するための化合物および組成物
JP6240083B2 (ja) 樹状細胞癌ワクチンのための小分子エンハンサー
CN115702147A (zh) Trex1的调节剂
PL153459B1 (en) A method of 3-azidenucleosides production
WO2022102715A1 (ja) 組み合わせ医薬組成物および治療方法